Auger Emitter Conjugated PARP Inhibitor for Therapy in Triple Negative Breast Cancers: A Comparative In-Vitro Study

Auger Emitter Conjugated PARP Inhibitor for Therapy in Triple Negative Breast Cancers: A Comparative In-Vitro Study

PARP1 inhibitors (PARPi) are currently approved for BRCA<sup>mut</sup> metastatic breast cancer, but they have shown limited response in triple negative breast cancer (TNBC) patients. Combination of an Auger emitter with PARPis enables PARP inhibition and DNA strand break induction simul...

Full description

Bibliographic Details
Main Authors: Ramya Ambur Sankaranarayanan, Jennifer Peil, Andreas T. J. Vogg, Carsten Bolm, Steven Terhorst, Arno Classen, Matthias Bauwens, Jochen Maurer, Felix Mottaghy, Agnieszka Morgenroth
Format: Article
Language:English
Published: MDPI AG 2022-01-01
Series:Cancers
Subjects:
Auger emitter
TNBC
PARP1 inhibitors
Online Access:https://www.mdpi.com/2072-6694/14/1/230

Internet

https://www.mdpi.com/2072-6694/14/1/230

Similar Items